Allogeneic Hematopoietic Stem Cell Transplant for Patients With Inborn Errors of Immunity | MicrobiomeTrials← Back to trialsNCT04339777
Allogeneic Hematopoietic Stem Cell Transplant for Patients With Inborn Errors of Immunity
RecruitingPHASE2INTERVENTIONAL
Trial Details
Start: 2020-09-22Est. Completion: 2028-10-01
Enrollment target: 66 participants Locations- National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Other microbiome trials you might be interested in
Relapsed Acute Myeloid LeukemiaRefractory Acute Myeloid LeukemiaB-cell Acute Lymphoblastic LeukemiaPediatric CancerPediatric ALL, RelapsedPediatric ALLPediatric ALL, B CellAcute Myeloid LeukemiaAcute Lymphoblastic LeukemiaPediatric AMLR/R AMLR/R B-cell ALL
The goal of this clinical trial is to learn if sonrotoclax (BGB-11417) is safe and may help treat children and adolescen…
Multiple LocationsEst. completion Apr 30, 2030
Phase 1
Recruiting
B-AllAcute Lymphoblastic Leukemia
Background:
B-cell acute lymphoblastic leukemia (B-ALL) is a type of blood cancer. Some people with B-ALL have a gene m…
Bethesda, United StatesEst. completion Jun 30, 2030
Acute Lymphoblastic LeukemiaB-All
Background:
Acute lymphoblastic leukemia (ALL) is a type of blood cancer. Chimeric antigen receptor (CAR) therapy invol…
Bethesda, United StatesEst. completion Jan 31, 2030